“Reduction in DLBCL recurrence achieved through dual-targeted therapy”

Dual-target therapy reduces DLBCL recurrence

Non-Hodgkin’s lymphoma is one of the ten most common cancers in Hong Kong, and diffuse large B-cell lymphoma (DLBCL) is the most common type, accounting for about 30% to 40% of cancers. Although the traditional treatment has achieved good results in the past 20 years, 40% of the patients still fail or relapse. Fortunately, there have been new advances in first-line treatment in recent years, and dual-target therapy can further reduce the risk of recurrence.

Liao Chongyu, a specialist in hematology and hematology oncology, said that there are about 400 new cases of DLBCL every year. Patients cover different age groups and are high-grade cancers. If they do not receive treatment, the median survival period is less than 1 year. “Patients often palpate lymph nodes or lumps in the neck, armpit, or groin, and may also experience symptoms such as loss of appetite, persistent fever, and night sweats.”

DLBCL loss of appetite

DLBCL loss of appetite

Recurrence in more than two years

The first-line treatment of traditional DLBCL is the anti-CD20 targeted drug called “R-CHOP” combined with chemotherapy and steroid therapy, which recognizes and binds to the CD20 antigen on cancer cells, and then triggers an immune response to kill cancer cells. Although the treatment effect is good, about 40% of patients will fail to treat or relapse, and most of the relapses occur within two years after diagnosis. Liao Chongyu continued, “Bone marrow transplantation, immunotherapy, chemotherapy, etc. are available for the treatment of relapsed patients. However, there are many complications in the treatment, which makes it difficult for patients. Research also shows that the median survival period of relapsed patients is only about 1 year.”

Read more:  From 6 hours to 3 days ... a new study reveals how long Corona remains in clothes

Entering cancer cells to release chemotherapy drugs

If the International Prognostic Index (IPI) is calculated based on factors such as age, tumor stage, and serum LDH, and the DLBCL patients are at a higher risk of recurrence, the latest dual-target therapy can be considered. In addition to reducing one chemotherapy drug), anti-CD79B antibody-drug complex was added for treatment. The anti-CD79B antibody-drug complex combines antibodies and chemotherapy drugs. When the CD79B antigen of cancer cells is recognized, the drugs will enter the cancer cells and release chemotherapy drugs to destroy them, reducing the impact on other cells. According to research, the dual-target therapy combination can reduce the risk of recurrence by 27% compared with the traditional single-target therapy combination.

Hematology and Hematology Oncology Specialist

Hematology and Hematology Oncology Specialist

Early treatment reduces pain

Ms. Zheng, 60 years old this year, developed pain in the right lumbar bone in 2014. She thought it was just sciatica, but in just 3 months, she changed from walking like a fly to walking with her right foot. When she consulted a doctor, she found a 10 cm large tumor in the right pelvis that caused her pelvic pain. Burst, and diagnosed with DLBCL stage III. After R-CHOP treatment and radiotherapy, he recovered, but unfortunately relapsed in 2016. After bone marrow transplantation and CAR-T cell therapy, he got rid of the cancer. She advises other DLBCL patients to face their condition calmly and positively, and to seek treatment advice from one or two more doctors, so as to grasp the golden period of treatment and reduce the pain of complications caused by treatment.

Read more:  beware of the boss's fear!, Management

Support for newly diagnosed patients

Chen Weijie, secretary of the Fellowship Alliance, is also a rehabilitated blood cancer (AML). He said that he was worried about recurrence for several years, so it is very important to reduce the risk of recurrence; Liang Jiaer, chairman of the Hong Kong Bone Marrow Transplant Rehabilitation Association, hoped to care more about patients and provide support. The two patient organizations jointly launched the “Multiple New Attitudes” anti-cancer care plan, hoping to help newly diagnosed DLBCL patients manage their disease. Provide emotional support or dietary guidelines suggested by a registered dietitian, free of charge, interested parties can WhatsApp 6316 0566 to sign up.”

Originally published on AM730

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Editor's Pick